End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
59.8 CNY | +3.64% | +2.75% | -30.48% |
Apr. 29 | MGI Tech Showcases Life Science Excellence At ESCMID Global 2024 with Latest DNBSEQ-E25 Sequencer | CI |
Apr. 28 | MGI Tech Co. Ltd. Opens Customer Experience Center in Brazil | CI |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- Growth progress expectations are rather promising. Indeed, sales are expected to rise sharply in the coming years.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- The company has insufficient levels of profitability.
- Based on current prices, the company has particularly high valuation levels.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Sector: Advanced Medical Equipment & Technology
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-30.48% | 3.41B | - | ||
+8.07% | 219B | B | ||
+7.87% | 185B | B- | ||
+12.75% | 135B | B- | ||
-1.33% | 62.21B | A- | ||
+4.88% | 51.01B | B+ | ||
+11.59% | 51.28B | B+ | ||
+2.71% | 41.85B | A | ||
+4.90% | 37.02B | - | ||
+23.75% | 31.27B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- 688114 Stock
- Ratings MGI Tech Co., Ltd.